Neuronetics (STIM) Set to Release Earnings on Wednesday

Neuronetics (NASDAQ:STIM) is projected to post its Q3 2026 results before the market opens on Wednesday, November 4th. Analysts expect the company to announce earnings of ($0.08) per share and revenue of $40.42 million for the quarter. Investors may review the information on the company’s upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Wednesday, November 4, 2026 at 8:30 AM ET.

Neuronetics (NASDAQ:STIM) last issued its earnings results on Tuesday, August 11th. The company reported ($0.05) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.12) by $0.07. The company had revenue of $41.57 million for the quarter, compared to the consensus estimate of $40.17 million. On average, analysts expect Neuronetics to post ($0.33) EPS for the current fiscal year and ($0.25) EPS for the next fiscal year.

Neuronetics Stock Performance

Neuronetics stock opened at $2.19 on Wednesday. The business has a 50-day moving average of $2.57 and a 200-day moving average of $1.87. Neuronetics has a 1 year low of $0.80 and a 1 year high of $3.44.

Insider Buying and Selling at Neuronetics

In other Neuronetics news, major shareholder Jorey Chernett purchased 14,000 shares of the firm’s stock in a transaction on Friday, August 14th. The stock was purchased at an average cost of $3.16 per share, for a total transaction of $44,240.00. Following the transaction, the insider owned 10,602,988 shares in the company, valued at $33,505,442.08. The trade was a 0.13% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Company insiders own 8.40% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have weighed in on the company. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Neuronetics in a research report on Monday, September 14th. BTIG Research reissued a “buy” rating and set a $6.00 price target on shares of Neuronetics in a research report on Thursday, September 17th. Wall Street Zen upgraded shares of Neuronetics from a “sell” rating to a “hold” rating in a report on Sunday, July 12th. B. Riley Financial started coverage on Neuronetics in a research note on Friday, September 11th. They set a “buy” rating on the stock. Finally, Citigroup reaffirmed a “market outperform” rating on shares of Neuronetics in a report on Tuesday, July 21st. Four equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $4.67.

About Neuronetics

Neuronetics, Inc is a medical technology company that develops and commercializes noninvasive treatments for psychiatric and neurological disorders. Its primary product is NeuroStar TMS Therapy, which uses transcranial magnetic stimulation to deliver targeted magnetic pulses to areas of the brain associated with mood regulation.

NeuroStar TMS Therapy is cleared by the U.S. Food and Drug Administration for treating major depressive disorder in adults and adolescents, obsessive-compulsive disorder, and depression with anxious distress.